BSE filing, NSE: DWARKESH. Summary written from the filing by ALFA Finder's alert engine.
Dwarikesh Sugar Industries Ltd: key numbers
- Share price
- ₹40.65
- Market cap
- ₹753.2 Cr
- Revenue (annual)
- ₹1,402 Cr
- Net profit (annual)
- ₹30.84 Cr
- P/E (TTM)
- 52.0×Sector 26.8×
- Promoter holding
- 42.14%+0.00% QoQ
- FII holding
- 1.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dwarikesh Sugar Industries Ltd
All →Dwarikesh Sugar Industries Board Meeting Date
Dwarikesh Sugar intimated its Board meeting scheduled for October 29, 2026. The agenda covers Q2 FY27 unaudited results and independent director continuations.
Dwarikesh Sugar Industries Credit Rating
ICRA withdrew Dwarikesh Sugar's A1 rating on its ₹300 crore Commercial Paper at the company's request. Long-term A+ (Stable) ratings on ₹600 crore facilities were re-affirmed.
Dwarikesh Sugar Industries Price Movement Clarification
Dwarikesh Sugar Industries clarified that recent stock price fluctuations are market-driven. The company confirmed no unpublished price sensitive information exists that requires disclosure to exchanges.
Dwarikesh Sugar Industries Management Change
Dwarikesh Sugar Industries announced the reappointment of Shri Gautam R. Morarka as Whole Time Director and Executive Chairman, following approval at the 32nd AGM.
- Execution
- 5 (five) consecutive years
Dwarikesh Sugar Industries Annual General Meeting
Dwarikesh Sugar Industries held its 32nd Annual General Meeting on August 6, 2026. Shareholders transacted business including adoption of accounts, dividend declaration, and director re-appointments.
Dwarikesh Sugar Industries Investor Presentation: Key Takeaways
Dwarikesh Sugar reported a weak Q1FY27 with a loss of INR 257.3 million, hit by the absence of sugarcane crushing and lower ethanol sales.
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.